Key players operating in the gastric motility disorder drug market are Pfizer Inc., Takeda Pharmaceutical Company Limited, Janssen Pharmaceuticals, Sun Pharmaceutical Industries Ltd., AbbVie Inc., Boehringer Ingelheim, Eli Lilly and Company, Bristol Myers Squibb, Daiichi Sankyo Company, Limited, Bausch Health Companies, Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals, Eisai Co., Ltd., Ferring Pharmaceuticals, UCB, Evoke Pharma, and Cadila Pharmaceuticals.

The rising prevalence of gastrointestinal disorders, increasing demand for non-invasive treatment options, and growing awareness regarding gastric disorders are fueling the growth of the gastric motility disorder drug market. According to the World Gastroenterology Organisation, over 2 million individuals worldwide are affected by gastrointestinal motility disorders annually.

Key players are focusing on expansion in high growth markets through acquisitions and collaborations. Manufacturers are also investing in developing novel drug formulations and delivery systems to provide cost-effective treatment options for gastric motility disorders. For instance, in 2020, Evoke Pharma and EVERSANA entered into an agreement for commercializing Gimoti in the United States. Such expansions are expected to surge the demand for gastric motility disorder drugs globally.

Market Drivers

The increasing healthcare expenditure per capita and growing emphasis on research & development activities for gastrointestinal disorders are expected to drive the gastric motility disorder drug market. Additionally, changing lifestyle, rising consumption of unhealthy food, increase in stress levels, and growing geriatric population are some other factors projected to propel the demand for gastric motility disorder medications over the forecast period. However, side effects associated with certain prokinetic drugs and lack of established treatment options for rare gastric motility disorders may impede the market growth.

The current geopolitical tensions and conflicts are negatively impacting the growth of the gastric motility disorder drug market. Since many drugs for gastric motility disorders are imported from other countries and regions, the disruptions in international trade and increasing economic sanctions imposed by some countries on others are hindering the easy availability of these drugs in several markets. This is adversely affecting the treatment rates for various gastric motility disorders like gastroparesis and constipation-predominant IBS.

Rising geopolitical risks are also raising the input costs for drug manufacturers due to higher costs of active pharmaceutical ingredients, raw materials, and logistics. This is likely to force many companies to hike the prices of gastric motility disorder drugs in the coming years. Higher drug prices can reduce the affordability and compliance rates among patients from low and middle-income countries which are grappling with economic distress and high inflation. Additionally, the diversion of healthcare budgets towards dealing with conflicts and emergencies is leaving lesser funds available for gastrointestinal disorders treatment and research.

To mitigate the impact of unfavorable geopolitical environment, companies in the gastric motility disorder drug market need to diversify their manufacturing and supply chain network across multiple regions. Establishing local production facilities and tying up with regional partners can help ensure steady supplies. Companies also need to offer discounted prices or patient assistance programs in developing nations to boost access to treatment. Moreover, investing in developing novel and affordable drug delivery technologies can help address the specific needs of patients from low resource settings.

In terms of value, North America holds the largest share in the global gastric motility disorder drug market due to the rising prevalence of gastric motility disorders, strong reimbursement structure, availability of advanced healthcare facilities and growing awareness among people about these conditions. Furthermore, the presence of leading manufacturers in the US contributes to the dominance of the North American region.

Asia Pacific is poised to be the fastest-growing regional market for gastric motility disorder drugs over the forecast period. Factors such as the improving access to healthcare in many Asian countries, rising affordability of diagnosis and treatment and increasing healthcare spending are supporting the growth of the gastric motility drug market in the Asia Pacific region. China and India with their huge populations and growing elderly demographics suffering from gastrointestinal issues are emerging as lucrative markets.

The current geopolitical tensions and conflicts are negatively impacting the growth of the gastric motility disorder drug market. Since many drugs for gastric motility disorders are imported from other countries and regions, the disruptions in international trade and increasing economic sanctions imposed by some countries on others are hindering the easy availability of these drugs in several markets. This is adversely affecting the treatment rates for various gastric motility disorders like gastroparesis and constipation-predominant IBS.

Rising geopolitical risks are also raising the input costs for drug manufacturers due to higher costs of active pharmaceutical ingredients, raw materials, and logistics. This is likely to force many companies to hike the prices of gastric motility disorder drugs in the coming years. Higher drug prices can reduce the affordability and compliance rates among patients from low and middle-income countries which are grappling with economic distress and high inflation. Additionally, the diversion of healthcare budgets towards dealing with conflicts and emergencies is leaving lesser funds available for gastrointestinal disorders treatment and research.

To mitigate the impact of unfavorable geopolitical environment, companies in the gastric motility disorder drug market need to diversify their manufacturing and supply chain network across multiple regions. Establishing local production facilities and tying up with regional partners can help ensure steady supplies. Companies also need to offer discounted prices or patient assistance programs in developing nations to boost access to treatment. Moreover, investing in developing novel and affordable drug delivery technologies can help address the specific needs of patients from low resource settings.

Get More Insights On This Topic: Gastric Motility Drug Market